Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy D Shapiro

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2021
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia BJan Astermark, Katharina Holstein, Yasmina L Abajas, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
Blood Advances|March 15, 2022
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitorsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Blood|May 22, 2025
Plasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismYaqiu Sang, Marzia Menegatti, Jennifer A Brody, et al.
Blood|August 25, 2019
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial resultsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Science Advances|November 21, 2017
A null mutation in <i>SERPINE1</i> protects against biological aging in humansSadiya S Khan, Sanjiv J Shah, Ekaterina Klyachko, et al.
Blood|December 27, 2011
VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American populationDaniel B Bellissimo, Pamela A Christopherson, Veronica H Flood, et al.
Blood Advances|February 27, 2023
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia BAmy D Shapiro, Roshni Kulkarni, Margaret V Ragni, et al.
Blood Advances|January 7, 2026
Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 studyJohnny Mahlangu, Ana Boban, Maria Bruzelius, et al.
The Lancet. Haematology|January 30, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyClaude Négrier, Johnny Mahlangu, Michaela Lehle, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2021
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia BJan Astermark, Katharina Holstein, Yasmina L Abajas, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
Blood Advances|March 15, 2022
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitorsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Blood|May 22, 2025
Plasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismYaqiu Sang, Marzia Menegatti, Jennifer A Brody, et al.
Blood|August 25, 2019
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial resultsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Science Advances|November 21, 2017
A null mutation in <i>SERPINE1</i> protects against biological aging in humansSadiya S Khan, Sanjiv J Shah, Ekaterina Klyachko, et al.
Blood|December 27, 2011
VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American populationDaniel B Bellissimo, Pamela A Christopherson, Veronica H Flood, et al.
Blood Advances|February 27, 2023
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia BAmy D Shapiro, Roshni Kulkarni, Margaret V Ragni, et al.
Blood Advances|January 7, 2026
Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 studyJohnny Mahlangu, Ana Boban, Maria Bruzelius, et al.
The Lancet. Haematology|January 30, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyClaude Négrier, Johnny Mahlangu, Michaela Lehle, et al.
Pageof 8